compounded semaglutide crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA warns against compounded versions
Description
10.2337/dc23-S009 2
While the FDA has concluded that there is no evidence that GLP-1s cause suicidal ideation, researchers are continuing to carefully evaluate any changes in mental health
In HF, when mitochondrial oxidative metabolism and ATP synthesis decrease, it is frequently offset by an augmented glycolytic response (61)
SGLT2 [sodium-glucose cotransporter 2] inhibitors initially seemed to be linked with an even lower risk of uveitis compared to GLP-1 receptor agonists, but after doing a sensitivity analysis of patients on monotherapy, we no longer found that association
